XING AG

  • WKN: XNG888
  • ISIN: DE000XNG8888
  • Land: Deutschland

Nachricht vom 07.09.2010 | 15:39

XING AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution


XING AG / Release of an announcement according to Article 21, Section 1
of the WpHG [the German Securities Trading Act] (share)

07.09.2010 15:39

Dissemination of a Voting Rights Announcement, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

Baillie Gifford Overseas Ltd., Edinburgh, Scotland, has informed us on September 6, 2010 as follows: 1. Baillie Gifford Overseas Limited, Edinburgh, Scotland We hereby give notice, pursuant to sec. 21 para. 1 of the WpHG, that on 3 September 2010 the voting interest of Baillie Gifford Overseas Limited, Edinburgh, Scotland in XING AG exceeded the 3 percent threshold and on this date amounted to 3.10% (this corresponds 163,500 voting rights). All of these voting rights (this corresponds to 163,500 voting rights) are attributed to Baillie Gifford Overseas Limited in accordance with sec. 22 para. 1 sent. 1 no. 6 WpHG. 2. Baillie Gifford & Co, Edinburgh, Scotland We hereby give notice, pursuant to sec. 21 para. 1 of the WpHG, that on 3 September 2010 the voting interest of Baillie Gifford & Co, Edinburgh, Scotland in XING AG exceeded the 3 percent threshold and on this date amounted to 3.10% (this corresponds 163,500 voting rights). All of these voting rights (this corresponds to 163,500 voting rights) are attributed to Baillie Gifford & Co in accordance with sec. 22 para. 1 sent. 1 no. 6 and sent. 2 of the WpHG (via Baillie Gifford Overseas Limited). XING AG, Hamburg, Germany 07.09.2010 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English Company: XING AG Gänsemarkt 43 20354 Hamburg Deutschland Internet: www.xing.com End of Announcement DGAP News-Service

GBC im Fokus

MagForce AG:

Die kommerzielle Behandlung mit der MagForce-Technologie wird nun auch vom Klinikum Vivantes Friedrichshain abgedeckt. Damit kommt diese neue Technologie bereits in vier Kliniken in Deutschland für die kommerzielle Behandlung bösartiger Hirntumore zum Einsatz, was als eine gute Basis für einen Anstieg der Behandlungsumsätze anzusehen ist. Parallel dazu rechnen wir mit der Marktzulassung zur Behandlung von Prostatakrebs in den USA zum Ende des Geschäftsjahres 2017. Wir vergeben das Rating KAUFEN.

News im Fokus

Deutsche Post AG: Informationen zum Aktienrückkauf - 2. Tranche

27. Mai 2016, 17:05

Aktueller Webcast

windeln.de AG

Q1 2016 Earnings Call

24. Mai 2016

Aktuelle Research-Studie

Edel AG

Original-Research: Edel AG (von Montega AG): Kaufen

26. Mai 2016